{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:41:42Z","timestamp":1789465302705,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) with preserved (HFpEF) and mildly reduced (HFmrEF) ejection fraction are prevalent, yet frequently underdiagnosed syndromes associated with high morbidity and mortality, impaired quality of life, and escalating healthcare expenditures. Although guideline-directed medications like SGLT2 inhibitors have been shown to reduce the risk of hospitalization and cardiovascular death, their use remains limited and substantial residual risk persists. This trial aims to evaluate the safety and performance of a novel left-atrium-to-coronary-sinus shunt (Edwards APTURE transcatheter shunt system) in HFpEF and HFmrEF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ALT-FLOW II is a prospective multi-centre, randomized, sham-controlled, double-blinded (patient and assessor) trial. Approximately 100 symptomatic HF patients aged \u226518 years with left ventricular ejection fraction &amp;gt;40% and exercise pulmonary capillary wedge pressure (PCWP) \u226525\u2005mm Hg with a PCWP to right atrial pressure gradient \u22658\u2005mm Hg will be randomized 1:1 to the APTURE shunt vs sham control. Key exclusion criteria include severe HF, significant valvular disease, and more than mild right ventricular dysfunction. The primary endpoints are the safety of the APTURE device at 30 days and change in workload-corrected PCWP normalized to bodyweight at 6 months. Secondary endpoints include changes in patient-reported outcomes, and hemodynamic and echocardiographic parameters through 5 years. The trial will also explore the impact of the device on short-term cardiac remodelling and intra-cardiac flow patterns using multi-modality imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ALT-FLOW II trial will evaluate the safety and performance of the APTURE system in symptomatic HFpEF and HFmrEF patients with elevated left atrial pressure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuaf016","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:31:26Z","timestamp":1767702686000},"page":"563-571","source":"Crossref","is-referenced-by-count":1,"title":["Rationale and design of a randomized, sham-controlled, clinical trial for evaluation of the Edwards APTURE transcatheter shunt system (ALT-FLOW II)"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-127X","authenticated-orcid":false,"given":"Dean J","family":"Kereiakes","sequence":"first","affiliation":[{"name":"Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Heart and Vascular Institute , 2123 Auburn Ave., Ste., 424, Cincinnati, OH 45219 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-7722","authenticated-orcid":false,"given":"Ryan J","family":"Tedford","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Medical University of South Carolina (MUSC) , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Main Line Health , Wynnewood, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-8880","authenticated-orcid":false,"given":"Firas","family":"Zahr","sequence":"additional","affiliation":[{"name":"Department of cardiology, Knight Cardiovascular Institute, Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Lurz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Mainz , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1363","authenticated-orcid":false,"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J","family":"Baron","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital , Boston, MA ,","place":["USA"]},{"name":"Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o L","family":"Cavalcante","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center and Core Lab, Minneapolis Heart Institute Foundation, Allina Health Minneapolis Heart Institute , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich P","family":"Jorde","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Montefiore Health System , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9527-0852","authenticated-orcid":false,"given":"John R","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2909","authenticated-orcid":false,"given":"Rami","family":"Kahwash","sequence":"additional","affiliation":[{"name":"Division of Cardiology, The Ohio State University , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M","family":"Lilly","sequence":"additional","affiliation":[{"name":"Division of Cardiology, The Ohio State University , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2653-6762","authenticated-orcid":false,"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, INSELSPITAL, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-6933","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Harrington","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026091504185114300_xuaf016-B1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"2026091504185114300_xuaf016-B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091504185114300_xuaf016-B3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/00325481.2020.1842621","article-title":"Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system","volume":"133","author":"Toth","year":"2021","journal-title":"Postgrad Med"},{"key":"2026091504185114300_xuaf016-B4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ejhf.3115","article-title":"Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction","volume":"26","author":"Wu","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"2026091504185114300_xuaf016-B6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"2026091504185114300_xuaf016-B7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jchf.2020.03.008","article-title":"Impaired exercise tolerance in heart failure with preserved ejection fraction: quantification of multiorgan system reserve capacity","volume":"8","author":"Nayor","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B9","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091504185114300_xuaf016-B10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s0140-6736(24)01643-x","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"2026091504185114300_xuaf016-B11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091504185114300_xuaf016-B12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091504185114300_xuaf016-B13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091504185114300_xuaf016-B14","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas city cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091504185114300_xuaf016-B15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jchf.2023.03.024","article-title":"Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the department of veterans affairs","volume":"11","author":"Hussain","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jchf.2023.05.006","article-title":"Overcoming barriers to use of SGLT2 inhibitor therapy: the battle against clinical inertia","volume":"11","author":"Greene","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jchf.2024.03.006","article-title":"Cost-effectiveness of medical therapy for heart failure with mildly reduced and preserved ejection fraction","volume":"12","author":"Dixit","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026091504185114300_xuaf016-B19","doi-asserted-by":"publisher","first-page":"e008293","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026091504185114300_xuaf016-B20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial","volume":"137","author":"Feldman","year":"2018","journal-title":"Circulation"},{"key":"2026091504185114300_xuaf016-B21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jamacardio.2024.2612","article-title":"Endovascular ablation of the greater splanchnic nerve in heart failure with preserved ejection fraction: the REBALANCE-HF randomized clinical trial","volume":"9","author":"Fudim","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026091504185114300_xuaf016-B22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jchf.2025.02.003","article-title":"Left atrial-to-coronary Sinus shunting in heart failure with mildly reduced or preserved ejection fraction: the ALT-FLOW trial (early feasibility study) 2-year results","volume":"13","author":"Fioretti","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am Heart J"},{"key":"2026091504185114300_xuaf016-B24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026091504185114300_xuaf016-B25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.amjcard.2007.12.014","article-title":"Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (&gt; or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (&lt;40%) fractions","volume":"101","author":"Sweitzer","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026091504185114300_xuaf016-B26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jchf.2017.06.013","article-title":"Heart failure with mid-range (borderline) ejection fraction: clinical implications and future directions","volume":"5","author":"Hsu","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026091504185114300_xuaf016-B27","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B28","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"2026091504185114300_xuaf016-B30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.124.070870","article-title":"Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial","volume":"150","author":"Stone","year":"2024","journal-title":"Circulation"},{"key":"2026091504185114300_xuaf016-B31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ejhf.417","article-title":"Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications","volume":"17","author":"Melenovsky","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.111.051540","article-title":"Pulmonary capillary wedge pressure augments right ventricular pulsatile loading","volume":"125","author":"Tedford","year":"2012","journal-title":"Circulation"},{"key":"2026091504185114300_xuaf016-B33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cardfail.2025.02.005","article-title":"PCWL: a compelling hemodynamic metric in advancing HFpEF","volume":"31","author":"Silkowski","year":"2025","journal-title":"Diagnosis J Card Fail"},{"key":"2026091504185114300_xuaf016-B34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ehf2.13697","article-title":"Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction","volume":"9","author":"Deis","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026091504185114300_xuaf016-B35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ehf2.12350","article-title":"Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction","volume":"6","author":"Kaye","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026091504185114300_xuaf016-B36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.976","article-title":"Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026091504185114300_xuaf016-B37","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.3390\/jcm11195901","article-title":"Pulmonary capillary wedge pressure during exercise is prognostic for long-term survival in patients with symptomatic heart failure","volume":"11","author":"Ahlgrim","year":"2022","journal-title":"J Clin Med"},{"key":"2026091504185114300_xuaf016-B38","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/eurheartj\/ehu315","article-title":"Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction","volume":"35","author":"Dorfs","year":"2014","journal-title":"Eur Heart J"},{"key":"2026091504185114300_xuaf016-B39","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1016\/j.jscai.2023.101203","article-title":"Atrial shunt therapy for heart failure: an update","volume":"2","author":"Jagadeesan","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2026091504185114300_xuaf016-B40","doi-asserted-by":"publisher","first-page":"102439","DOI":"10.1016\/j.jscai.2024.102439","article-title":"Understanding right heart flow: implications for interatrial shunt device therapy in heart failure","volume":"4","author":"Guddeti","year":"2025","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2026091504185114300_xuaf016-B41","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/ehf2.15270","article-title":"Left atrial to coronary sinus shunting in more advanced heart failure with preserved ejection fraction","volume":"12","author":"Tedford","year":"2025","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuaf016\/66271198\/xuaf016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/563\/66271198\/xuaf016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/563\/66271198\/xuaf016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:23:46Z","timestamp":1789460626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/3\/563\/8415028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuaf016","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,8]]}}}